News | April 03, 2012

Study warrants focus on contrast-induced nephropathy

April 3, 2012 — Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. Researchers said the findings warrant more focus on implementation of a contrast-induced nephropathy (CIN) protocol to reduce complications.

The study, conducted Oct. 1, 2008 to Sept. 30, 2010, was designed to report two-year trends in PCI-associated renal failure. The study group included all Medicare patients admitted for a PCI without CABG (coronary artery bypass graft) surgery or valve surgery in an acute care hospital. The study population was divided into two sub-samples:

  • Elective PCI: Patients who did not have primary ST segment elevation myocardial infarction (STEMI) and did not arrive in cardiogenic shock or cardiac arrest.
  • Non-Elective PCI: All MBs not undergoing an elective PCI.

 

All patients studied experienced significant increases in both acute renal failure (ARF) and new hemodialysis (HD) year over year, by 29 percent and 21 percent, respectively. The percentage increase for both complications was slightly higher for those patients undergoing elective PCI, while the increase in ARF among patients undergoing non-elective PCI was nearly double that of elective patients.

“The rise in renal complications is concerning, given their close association with worse morbidity and mortality,” said April Simon, R.N., MSN, one of the researchers and president of Cardiac Data Solutions, which conduced the study. “This data suggests that increased focus on contrast-induced nephropathy prevention protocols may improve clinical outcomes. Any patient receiving contrast is at risk for CIN; insuring that the amount of contrast is minimized and paying particular attention to hydration are imperative.”

For more information: www.ereleases.com/pic/Cardiac-Data-Solutions.pdf.


Related Content

News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

October 17, 2023 — Halo Precision Diagnostics, a leader in early disease detection using precision diagnostics, today ...

Time October 17, 2023
arrow
News | Computed Tomography (CT)

September 19, 2023 — An advanced CT test can identify individuals with stable angina at a reduced risk of three-year ...

Time September 19, 2023
arrow
Subscribe Now